Antifungal drug resistance: An emerging problem in Mexico;La resistencia a los antifúngicos: Un problema emergente en México

Gaceta Medica de Mexico

Volumn 144, Issue 1, 2008, Pages 23-26

  Manzano Gayosso, Patricia ^a,c   Méndez Tovar, Luis J ^b   Hernández Hernández, Francisca ^a   López Martínez, Rubén ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antifungal resistance; Azoles; Candida; Dermatophytes

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; CONTROLLED STUDY; DERMATOMYCOSIS; DERMATOPHYTE; EPSILOMETER TEST; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MEXICO; NONHUMAN; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS;

ADULT; ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; CANDIDA; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MALE; MEXICO;

EID: 50849113780     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hudson MM. Antifungal resistance and over-the-counter availability in the UK: a current perspective. J Antimicrob Chemother 2001;48:345-350.
2. Vesell ES. On the significance of host factors that affect drug disposition. Clin Pharmacol Ther 1982;31:1-7.
3. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis 2003;36:S31-S41.
4. Bradley MC, Leidich S, Isham N, Elewski BE, Ghannoum MA. Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. Mycoses 1999;42:S105-S110.
5. Chapman SW, Cleary JD, Rogers PD. Amphotericin B. En: Dismukes WE, Pappas PG, Sobel JD, editors. Clinical mycology. Philadelphia, EUA: Oxford University Press; 2003. pp. 33-48.
6. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988;1:187-217.
7. Horsburgh CR, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983;74:23-29.
8. Fox R, Neal KR, Leen CL, Ellis ME, Mandal BK. Fluconazole resistant Candida in AIDS. J Infect 1991;22:201-204.
9. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997;41:196-199.
10. Méndez-Tovar LJ, Serrano-Jaén L, Almeida-Arvizu VM. Cefotaxima más amikacina asociadas a inmunomodulación en el tratamiento de actinomicetoma resistente a tratamiento convencional. Gac Med Mex 1999;135:517-521.
11. . Serrano-Jaen L, Méndez-Tovar LJ, Almeida-Arvizu V, Manzano-Gayosso P, Cordóva-Martínez E, Bazán-Mora E, et al. Dermatofitosis diseminada crónica asociada a fagocitosis deficiente tratada con antimicóticos e inmunoestimulación fagocitaria. Gac Med Mex 2006;142:415-417.
12. Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999;37:1480-1483.
13. Clinical Laboratory Standards Institute (CLSI). National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002.
14. Clinical Laboratory Standards Institute (CLSI). National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002.
15. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, et al. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-193.
16. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-647.
17. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
18. Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998;38:S32-S36.
19. Da Silva-Barros ME, Hamdan JS. Determination of susceptibility/resistance to antifungal drugs of Trichophyton mentagrophytes isolates by a macrodilution method. Can J Microbiol 2005;51:983-987.
20. Santos DA, Hamdan JS. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 2006;44:357-362.
21. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-247.
22. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-517.
23. Carrillo-Muñoz AJ, Tur C, Estivill D, Montsant L, Carceller A, Hernández-Molina JM, et al. Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neoformans. Rev Iberoam Micol 1997;14:50-54.
24. Silva VV, Díaz JMC, Febré N, Red de Diagnóstico en Micología Médica. Vigilancia de la resistencia de levaduras a antifúngicos. Rev Chil Infec 2002;19:S149-S156.